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Abstract
Objectives: Enhanced recovery after surgery (ERAS) protocols are coming to represent the standard of
care in many surgical procedures, yet data on their use following hepatic surgery are scarce. The aim of
this study was to review outcomes after the introduction of an ERAS programme for patients undergoing
open hepatic resection.
Methods: A retrospective review of patients undergoing open hepatic resection from March 2005 to
June 2011 was carried out. The primary outcome measure was total hospital length of stay (LoS)
(including readmissions). Principles associated with enhanced recovery after surgery were documented
and analysed as independent predictors of hospital LoS.
Results: A total of 120 patients underwent 128 consecutive hepatic resections, 84 (65.6%) of which
were performed in patients with underlying colorectal metastases and 64 (50.0%) of which comprised
major hepatic resections. The median hospital LoS was reduced from 6 days to 3 days from the first to
the fourth quartiles of the study population (P = 0.021). The proportion of patients suffering complications
(26.6%) remained constant across the series. Readmissions increased from the first quartile (none of 32
patients) to the fourth quartile (seven of 32 patients) (P = 0.044). Following multivariate analysis, only the
development of a complication (P < 0.001), total postoperative i.v. fluid (P = 0.003) and formation of an
anastomosis (P = 0.006) were independent predictors of hospital LoS.
Conclusions: An ERAS programme can be successfully applied to patients undergoing open hepatic
resection with a reduction in hospital LoS, but an increase in the rate of readmissions.
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Introduction
Enhanced recovery after surgery (ERAS) programmes following
surgical interventions are now within the standard of care for
patients undergoing colorectal surgery. High-level evidence exists
to support their use.1 The magnitude of benefit to be derived from
such programmes in open surgery is greater than the effect of
conversion to laparoscopic surgery alone.2 However, data support-
ing the use of ERAS programmes after hepatic resection are rela-
tively scarce. A recent systematic review3 of ERAS programmes for
hepatic resections identified only three cohort studies4–6 of suffi-
cient quality to meet inclusion criteria for further analysis. The
results of two of these studies4,5 showed significant reductions in
hospital length of stay (LoS) of 2–3 days and, in addition, one
study5 showed a cost reduction in association with an ERAS pro-
gramme. No studies4–6 showed an increase in rates of readmis-
sions, complications or mortality. However, there are several
problems associated with these studies in that whether the avail-
able data are sufficiently powered to detect differences in the par-
ticular outcome measures used is questionable. Moreover, no
assessment of the effect on quality of life of ERAS programmes
was possible from the included studies.3 The authors of the sys-
tematic review also noted significant heterogeneity in the descrip-
tions of the methodologies of the ERAS programmes, which
indicates that these results must be interpreted with caution.3
Unlike clinical trials, in which samples of patients are rand-
omized to two or more interventions in order to resolve a specific
question, real-time clinical practice often involves evolution over
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time as new evidence becomes available and alterations in practice
take time to embed. Thus, the aims of this study were to review the
introduction of an ERAS programme into a single surgeon’s prac-
tice of hepatic resection over a 6-year period and, specifically, to
determine whether the gradual implementation of ERAS princi-
ples reduces hospital LoS.
Materials and methods
Patients undergoing hepatic resection were identified from a pro-
spective database of hepatic resections within a single surgeon’s
practice that had been compiled since the surgeon began working
at this centre. This surgeon was the major provider of non-
transplant hepatic surgery for patients normally resident in the
upper South Island of New Zealand; surgeries were undertaken at
Christchurch Hospital. A retrospective patient note review was
then performed. Standard demographic data and information on
diagnosis, intraoperative variables (blood loss and blood trans-
fused) and hospital LoS were collected prospectively. Other intra-
operative variables (use of nasogastric tubes, drains, use of
regional analgesia such as epidural or intrathecal morphine,
volume of i.v. fluids infused, use of continuous or intermittent
wound catheters), and postoperative variables (volume of i.v.
fluids infused, complications, non-use of steroids) were obtained
retrospectively from patient notes. The volume of i.v. fluids
infused was totalled at 24 h (excluding fluid given intraopera-
tively), 48 h and 72 h postoperatively and for the entire admission.
An anastomosis was defined as any entero-enteric or hepaticoje-
junostomy. Total hospital LoS was defined as the LoS in days from
the initial admission plus the LoS of any readmission that
occurred within 30 days of initial discharge. Readmission data
collected included time to readmission, reason for readmission
and duration of readmission. Readmission was defined as any
hospital readmission within 30 days of discharge; data were taken
from the electronic database used in the hospital and its sur-
rounding districts. There was only one hospital to which patients
could be readmitted. Postoperative death was defined as any death
within 90 days or within the same hospital admission or readmis-
sion. Hepatic resections were coded as sequential hepatic resec-
tions starting at one. Each admission for a hepatic resection was
treated as an independent event irrespective of whether the
patient had undergone a previous hepatic resection.
Clinical pathway
Clinical care outside clinical trials is not a static or dichotomous
event and practice evolves over time. During the time period
reviewed in this study, the principles of an ERAS protocol were
gradually introduced. The time-points at which these various
principles were introduced are documented for the purpose of
this study in Table 1. A full ERAS programme was then in place by
December 2009 (following hepatic resection number 79).
Preoperative patient counselling was delivered by the
surgeon and nurses in the outpatient department and standard
pre-admission clinic. No additional media were used. Plans for
discharge were discussed at these visits and included an expected
day of discharge.
Opioid-based, patient-controlled analgesia was used until the
patient felt comfortable about taking oral analgesia. Analgesia was
administered at the discretion of a dedicated pain relief team.
In the postoperative period, patients routinely returned to a
high-dependency unit in which one nurse was dedicated to two
patients. Patients were able to eat and drink without restriction on
return to this ward. Within 24 h patients returned to the normal
ward setting. Patients ideally returned to the home ward, but were
not co-located with other ERAS programme patients.
The management of i.v. fluids within the postoperative period
has evolved. Initially, fluid was often used to counteract epidural-
induced hypotension. After the switch to intrathecal morphine,
the consultant surgeon made a concentrated effort to minimize
the use of i.v. fluids. On their return to the ward, patients were
charted 60–80 ml/h of crystalloid until they were drinking well.
This was slowed to 20 ml/h within 12 h, as per the patient-
controlled analgesia protocol. Urine outputs of 10–20 ml/h were
tolerated. Nursing and junior medical staff were discouraged from
simply increasing i.v. fluid intake in response to low urine outputs,
and encouraged to make a complete assessment and use fluid
boluses with reassessment. This process took time to embed. The
overuse of 0.9% saline was discouraged. Routine weighing and
diuretics were not used. The consultant surgeon or a hepatopan-
creatobiliary fellow routinely made ward rounds twice per day.
Patients were deemed fit for discharge when their findings were
normal (including clinical assessment for hepatic dysfunction) and
pain was controlled with oral analgesia. They were also required to
demonstrate tolerance of an oral diet and to show that appropriate
social supports were in place. A bowel motion or passage of flatus
wasnot deemed tobe a requirement for discharge.Thebiochemical
and haematologic presence of jaundice, elevated C-reactive
protein, elevated prothrombin time and lowhaemoglobinwere not
contraindications todischargeper se,but trends in these factors and
evidence of stability were considered important.
To help alleviate patient concerns at the time of discharge and to
ensure that these patients had direct access to the surgical service, a
laminated credit card-sized card was developed. On one side, this
listed symptoms patients should look out for and gave details of
staff to contact in the event that they became concerned (i.e. the
surgeon’s mobile number, the direct line to the ward, the on-call
surgical registrar’s number). The other side of the card provided
advice to emergency doctors or general practitioners about which
blood tests to perform and who to contact if problems arose.
Patients referred to the tertiary centre from peripheral hospitals
were discharged to commercial facilities (at the expense of the
referring hospital) or to the care of relatives or friends within the
city if they did not require extra nursing care. They were asked to
remain within the city for a further week. All patients were
reviewed at 6–8 days after discharge in an outpatient clinic, at
which point their histology was communicated to them.
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Statistical analysis
Continuous variables are described as medians (ranges) and cat-
egorical variables as numbers and percentages as appropriate.
Univariate analysis was performed using the Mann–Whitney
U-test. Multiple linear regression was used to determine whether
specific perioperative factors were able to independently predict
LoS. To normalize the dependent variable (LoS), natural log trans-
formation was performed. Dummy variables were created for the
nominal variables. Stepwise multiple linear regression was also
performed to check for any anomalies in the data. Variables to be
included within the model were based on factors found to have
P-values of < 0.20 on univariate analysis. A P-value of < 0.05 was
considered to indicate statistical significance.
Results
Between March 2005 and June 2011, 129 patients were identified
from a prospectively collated database. Nine (7.0%) patients were
excluded from further analysis because they had undergoneminor
laparoscopic liver resection (n = 4), the proposed hepatic resection
had been abandoned when extrahepatic malignant disease was
found at laparotomy (n = 3), unexpected cirrhosis had been iden-
tified (n = 1) or they had undergone radiofrequency ablation
without hepatic resection (n = 1). The 120 (93.0%) patients
included in the study represented a total of 128 hospital admis-
sions for hepatic resection; these admissions comprised the final
dataset. Eight (6.7%) patients underwent two hepatic resections.
Demographics and pre- and intraoperative data are shown in
Table 2. Postoperative data are shown in Table 3.Overall, 34 of 128
(26.6%) hepatic resections were associated with the occurrence of
complications. These consisted of primary medical complications
(n = 12, 9.4%), including perioperative myocardial infarction
(n = 3), cardiac arrhythmia (n = 3), cardiac arrest (n = 1), dehy-
dration (n = 1), asthma exacerbation (n = 1), allergic reaction
(n = 1) and urinary tract infection (n = 1), atelectasis (n = 1),
hepatic dysfunction (n = 4, 3.1%), bile leak (n = 5, 3.9%), haem-
orrhage (n = 4, 3.1%), intra-abdominal abscess or collection (n =
4, 3.1%), anastomotic leak (n = 1, 0.8%), hernia (n = 1, 0.8%),
Table 1 Changes in the standard of care with the gradual implementation of an enhanced recovery after surgery (ERAS) protocol
Standard of care at commencement of study Changes to care by quartile
Preoperative care No changes
Admission on day of surgery
Oral carbohydrate loading
No bowel preparation or routine use of premedication
Prophylactic antibiotics on induction and at closure if the duration
of surgery exceeds 180 min
Intraoperative care Quartile 1
Anaesthesia with volatile anaesthetic, short-acting opioids and
anti-emetics
From hepatic resection 14: switch from epidural analgesia to
intrathecal morphine because of inability to provide an appropriate
post-epidural care package18
Intravenous fluids: titrated against central venous pressure (central
venous pressure targeted at <5 cmH2O intraoperatively, then
8 cmH2O in the early postoperative period)
From hepatic resection 27: introduction of bolus delivery (intermittent)
wound catheters with 40 ml 0.2% ropivacaine every 6 h for 3 days
with a 3-mg/kg loading dose at the time of closure
Intraoperative hypothermia was minimized by use of upper and
lower body warming devices
Quartile 3
All resections were performed by open surgery using transverse
incisions
From hepatic resection 79: commercial continuous delivery system of
0.2% ropivacaine
Not used routinely: drains, nasogastric tubes
Postoperative care Quartile 1
Deep vein thrombosis prophylaxis (20–40 mg enoxaparin
subcutaneously from the evening of surgery)
From hepatic resection 8: routine use of NSAIDs with omeprazole
cover at 24 h postoperatively
Analgesia: paracetamol 1 g q.i.d.
Opioid-based patient-controlled analgesia
Anti-emetics as required
Not used routinely: laxatives, diuretics, immunonutrition,
gabapentin19
Eat and drink as tolerated without restriction from day 0
Early mobilization
Urinary catheter removed at day 1
NSAIDs, non-steroidal anti-inflammatory drugs.
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ileus (n = 1, 0.8%) ischaemic gut (n = 1, 0.8%) and portal vein
thrombosis (n = 1, 0.8%). Two patients died in the postoperative
period, resulting in a mortality rate after hepatic resection of
1.6%. In both patients death occurred following prolonged hos-
pitalization (at 14 and 111 days, respectively) and resulted from
multi-organ failure; the initial complication was portal vein
thrombosis in the first patient and ischaemic gut in the second.
Overall, 15 patients (11.7%) were readmitted and required a
median of 3 days of additional hospitalization. Patients were read-
mitted for primary medical reasons (n = 5, 3.9%), including lower
respiratory tract infection (n = 2) and asthma exacerbation (n =
1), anaemia (n = 1), ascites (n = 1), bile leak (n = 3, 2.3%), wound
infection (n = 1, 0.8%), ileus (n = 1, 0.8%), intra-abdominal
collection (n = 3, 2.3%) and non-specific reasons in which no
cause for readmission was identified other than that the patient
felt safer in hospital (n = 2, 1.6%).
As Fig. 1 shows, median hospital LoS decreased across the
series, but the proportion of patients requiring readmission
increased as LoS reduced. The frequency of complications
remained constant throughout the series (Fig. 1). The median
total hospital LoS was 8 days (range: 2–111 days) in patients with
complications who were not readmitted and 12 days (range: 5–28
days) in those who were readmitted; however, this difference was
not statistically significant (P = 0.086). Univariate analysis
(Table 4) revealed 11 factors as statistically important in deter-
mining LoS. A further two factors had P-values of < 0.20 and were
included in a multivariate model. On multivariate analysis, three
factors remained as independent predictors of LoS: development
of a complication [coefficient: 1.84, 95% confidence interval (CI)
1.48–2.28; P < 0.001]; total volume of i.v. fluid received (coeffi-
cient: 1.68, 95% CI 1.39–2.02; P = 0.003), and presence of an
anastomosis (coefficient: 1.83, 95% CI 1.29–2.61; P = 0.006).
Because both the development of a complication and total i.v.
fluid received are likely to exhibit collinearity and occur post-
resection, and the presence of an anastomosis was also associated
with an increased LoS, the analysis was re-performed for only
those resections (n = 90) in which no complications or anastomo-
ses were noted so that factors directly related to the ERAS protocol
could be analysed in more detail (Table 5). From this, nine factors
were identified for inclusion in multivariate analysis and none of
these were shown to be independent predictors of hospital LoS.
Discussion
This study indicates that the introduction of an ERAS programme
for patients undergoing hepatic resection results in a significant
reduction inmedian LoS from 6 days at the commencement of the
study period to 3 days at the end of the study period. This magni-
tude in reduction is consistent with previous reports of outcomes
of fast-track hepatic resections.3 Themedian hospital LoS of 3 days
Table 2 Demographics and preoperative data for patients undergo-
ing hepatic resection during March 2005 to June 2011
Variable (n = 128 resections) Value
Age, years, median (range) 63 (35–82)
Cirrhosis, n (%) 4 (3%)
ASA score of 1 or 2, n (%) 104 (81%)
Diagnosis, n (%)
Colorectal metastases 84 (66%)
Cholangiocarcinoma 11 (9%)
Hepatocellular carcinoma 9 (7%)
Gastrointestinal stromal tumour
metastases
3 (2%)
Carcinoid metastases 4 (3%)
Other: benign/malignant 10/8 (8%/6%)
Intraoperative factors, n (%)
Major hepatectomy 64 (50%)
Anastomosis 10 (8%)
Epidural/intrathecal morphine/neither 9/111/8 (7%/87%/6%)
Wound catheter: nil/continuous/
intermittent
28/51/49 (22%/40%/38%)
Nasogastric tube 8 (6%)
Drain 25 (20%)
Blood loss, <0.5 l/0.5–1.0 l/>1.0 l 86/33/9 (67%/26%/7%)
Intraoperative transfusiona, units,
median (range)
0 (0–5)
aFifteen of 128 (11.7%) patients who underwent a hepatic resection
received a transfusion intraoperatively.
ASA, American Society of Anesthesiologists.
Table 3 Postoperative data for patients undergoing hepatic resec-
tion during March 2005 to June 2011
Variable (n = 128 resections) Value
Total i.v. fluids in first 24 h, l, median (range) 3 (0.25–10)
Total i.v. fluids in first 48 h, l, median (range) 1 (0–7)
Total i.v. fluids in first 72 h, l, median (range) 0 (0–4)
Total i.v. fluids, l, median (range) 4.6 (1–58)
Reintroduction of diet, day, median (range) 0 (0–15)
Patients using NSAIDs, n (%) 70 (55%)
Length of stay, days, median (range) 4 (2–111)
Patients readmitted, n (%) 14 (11%)
Time from discharge to readmission, days,
median (range)
3 (1–21)
Duration of readmission, days, median (range) 3 (1–16)
Reason for readmission, n (%)
Medical 4 (3%)
Bile leak 3 (2%)
Non-specific 2 (2%)
Wound infection 1 (1%)
Ileus 1 (1%)
Intra-abdominal collection/abscess 3 (2%)
NSAIDs, non-steroidal anti-inflammatory drugs.
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is, however, significantly less than that reported by previous
studies,4–6 including studies which referred to patients undergoing
laparoscopic hepatic resection.6 A small series by Stoot et al.6 of 26
patients undergoing laparoscopic hepatic resection showed a non-
significant reduction inmedianLoS from7days to 5 days following
the introduction of an ERAS protocol. This raises the issue of
whether greater focus should be given to optimizing the non-
technical aspects of an ERAS programme than to the institution of
minimally invasive surgery. This would seem particularly impor-
tant given that the similarities in economic costs between laparo-
scopic and open liver resection reported by several studies7,8
primarily derive from the decreased LoS, and because laparoscopic
resection is technically demanding and imposes a long learning
curve on the surgeon.9 It should, however, be acknowledged that
the current study did not assess other important issues, such as
return to work or normal activities, for which laparoscopic surgery
is likely to be of significant benefit compared with open surgery, as
has been seen in patients undergoing segmental colectomy,10 anti-
reflux surgery11 and cholecystectomy.12
In the two larger assessments of patients undergoing open
hepatic resection,4,5 median hospital LoS was 6 days and 7 days,
P = 0.003P = 0.066
16
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D
ay
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(P = 0.696)
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(P = 0.044)
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P = 0.021
Figure 1 Median hospital length of stay and proportion of patients
requiring readmission by quartile (n = 32 patients/quartile) in patients
undergoing open hepatic resection during March 2005 to June 2011
(n = 128)
Table 4 Univariate analysis of variable versus length of stay for
patients undergoing hepatic resection during March 2005 to June
2011
Variable (n = 128 resections) Days, median
(range)
P-value
Age, years, median (range)
Quartile 1: 48 (35–54) 4 (2–30)
Quartile 2: 60 (54–64) 4.5 (2–111) 0.204
Quartile 3: 66 (63–69) 4 (2–34) 0.555
Quartile 4: 76 (70–82) 5 (2–22) 0.113
ASA score: 1 or 2 (n = 104) 4 (2–34)
3 or 4 (n = 24) 6.5 (2–11) <0.001
Epidural (n = 9) 8.5 (5–30)
Intrathecal morphine (n = 111) 4 (2–111) 0.003
Blood loss: <0.5 l (n = 86) 4 (2–25)
0.5–1.0 l (n = 33) 4 (2–111) 0.148
>1.0 l (n = 9) 8 (5–30) 0.005
Hepatectomy: minor (n = 64) 4 (2–24)
Major (n = 64) 4 (2–111) 0.159
Anastomosis: No (n = 118) 11 (4–30)
Yes (n = 10) 4 (2–111) <0.001
Use of drain: No (n = 103) 4 (2–111)
Yes (n = 25) 8 (3–30) <0.001
NSAIDs use: No (n = 70) 5 (2–111)
Yes (n = 58) 4 (2–34) 0.001
Wound catheter use: None (n = 28) 4 (2–111)
Intermittent (n = 49) 4 (2–34) 0.159
Continuous (n = 51) 5 (2–30) 0.035
Postoperative i.v. fluid in first
24 h, median (range)
Quartile 1: 1 l (0–2 l) 4 (2–24)
Quartile 2: 2 l (2–3 l) 3 (2–25) 0.641
Quartile 3: 3 l (3–4 l) 3 (2–10) 0.850
Quartile 4: 5 l (4–9 l) 6 (2–34) 0.001
Total i.v. fluid, median (range)
Quartile 1: 2 l (0–3 l) 3 (2–22)
Quartile 2: 3 l (3–4 l) 3 (2–10) 0.200
Quartile 3: 5 l (4–7 l) 5 (2–24) 0.001
Quartile 4: 10 l (7–58 l) 6 (3–11) <0.001
Presence of complications
No (n = 94) 4 (2–24)
Yes (n = 34) 8 (2–111) <0.001
Hepatic resection number
Quartile 1 6 (2–30)
Quartile 2 4 (2–111) 0.066
Quartile 3 4 (2–34) 0.003
Quartile 4 3 (2–24) 0.021
ASA, American Society of Anesthesiologists; NSAIDs, non-steroidal anti-
inflammatory drugs.
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respectively. Again, the current study would appear to have
significantly improved on these figures, but this improvement
comes at the cost of an increased readmission rate, which began to
climb oncemedian LoS fell below 4 days and reached levels as high
as 21.9%. Despite this, the median total LoS (which includes
readmission days) remained significantly lower than the median
LoS recorded earlier in the study period. This highlights the
importance of early after-care and follow-up for patients in an
ERAS programme. Ensuring that patients are seen by medical
teams who are aware of potential postoperative complications
following hepatic resection is crucial to the success of such a
programme and to minimizing the costs of readmission. Despite
the increase in readmissions, the rate of complications did not
increase and remained stable throughout the series. Previous
studies13,14 have reported both an increasing readmission rate and
decreasing complication rate in association with ERAS pro-
grammes. Whether there is an optimal duration of hospital stay
that minimizes readmissions but maintains the reduced hospital
LoS cannot be determined by this study. It may also be possible
that significant cultural differences exist between the current
study and previous reports with respect to discharge practice. For
example, Lin and colleagues5 reported a pre-planned discharge
date at 6 days post-surgery, which may have caused their patients
to believe that discharge prior to this date was too early. A further
possibility, although this is difficult to determine in a retrospective
analysis, is that the behaviour of the surgical team changed over
time, resulting in earlier discharge. However, it should be noted
that the discharge criteria remained the same throughout the
period of study.
The introduction of the ERAS programme at this centre
required an evolution in clinical practice over time. It has taken
time to implement and embed changes such as those pertaining
to the use of intrathecal morphine, the routine use of wound
catheters, non-steroidal anti-inflammatory drugs (NSAIDs) and
omeprazole, and the limiting of postoperative i.v. fluids. These
are now implemented as standard practice. The protocols of
ERAS programmes are multifaceted and it is not clear which
factors are crucial to their success. In fact, although the present
study found an overall reduction in the duration of hospitaliza-
tion, multivariate analysis excluding data for patients in whom
postoperative complications were noted did not reveal any indi-
vidual factor as an independent predictor of hospital LoS. These
results further support the suggestion that it is the package of
care that is of most benefit, rather than any of the individual
factors. Whether further improvements can be achieved by the
addition of postoperative diuretics to maintain preoperative
weight or the use of opioid-sparing analgesics remains to be
determined.
The current results appear to indicate that not much more can
be gained in terms of reducing hospital LoS as it would seem
unlikely that day-case hepatic resection would be considered sen-
sible, given the potential for significant haemorrhage. Perhaps
further studies should focus onmeasuring and improving data for
quality of life in the intermediate postoperative period. Laparo-
scopic resection may have a role of significant benefit in this area.
Additionally, early identification (prior to discharge) of patients
who are likely to develop complications would be useful and
would allow for the tailoring of hospital LoS.
The limitations of this study include the fact that it was retro-
spective, but it is unlikely that any readmissions or complications
were missed because patients in this area can be readmitted to
only one hospital and patients were followed up in clinic prior to
Table 5 Univariate analysis of variables by length of stay for those
patients who did not have an anastomosis or a postoperative com-
plication following hepatic resection during March 2005 to June
2011
Variable (n = 90) Days, median
(range)
P-value
Age, years, median (range)
Quartile 1: 49.5 (35–54) 3 (2–6)
Quartile 2: 60 (55–63) 4 (2–24) 0.276
Quartile 3: 66 (63–69) 3 (2–21) 0.919
Quartile 4: 74.5 (64–80) 4 (2–10) 0.280
ASA score: 1 or 2 (n = 80) 3 (2–24)
3 or 4 (n = 10) 4.5 (2–21) 0.036
Epidural (n = 5) 6 (5–10)
Intrathecal morphine (n = 78) 3 (2–24) 0.003
Blood loss: <0.5 l (n = 62) 3 (2–24)
0.5–1.0 l (n = 24) 4 (2–17) 0.114
>1.0 l (n = 4) 6 (5–10) 0.005
Hepatectomy: minor (n = 48) 3 (2–24)
Major (n = 42) 4 (2–21) 0.161
Use of drain: No (n = 82) 3 (2–24)
Yes (n = 8) 5 (4–10) 0.004
NSAIDs use: No (n = 35) 4 (2–21)
Yes (n = 8) 3 (2–24) 0.204
Wound catheter use: None (n = 20) 4 (2–10)
Intermittent (n = 33) 3 (2–6) 0.300
Continuous (n = 37) 3 (2–24) 0.013
Postoperative i.v. fluid in first 24 h,
median (range)
Quartile 1: 1 l (0–2 l) 4 (2–24)
Quartile 2: 2 l (2–3 l) 3 (2–5) 0.099
Quartile 3: 3.5 l (3–8 l) 3 (2–10) 0.449
Quartile 4: 4 l (3–9 l) 4.5 (2–21) 0.162
Hepatic resection number
Quartile 1 4 (2–10)
Quartile 2 3 (2–6) 0.082
Quartile 3 3 (2–10) 0.015
Quartile 4 3 (2–24) 0.091
ASA, American Society of Anesthesiologists; NSAIDs, non-steroidal anti-
inflammatory drugs.
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discharge to their primary doctors. In addition, this hospital and
its surrounding districts now use a single electronic health record,
which makes data review more reliable. It should also be recog-
nized that this population of patients consisted almost exclusively
of fit patients with normal underlying hepatic parenchyma,
although it did include patients with hilar cholangiocarcinoma, in
whom morbidity and mortality have traditionally been high.15
Because of the study’s retrospective nature, it did not assess
quality of life or return to normal activities, which would seem to
be important factors to be included in future research. Another
factor that is hard to account for retrospectively concerns the
change in patient expectations that develops as the surgeon
becomes more experienced and thereby more confident of achiev-
ing a shortened LoS. Furthermore, because the return of gastroin-
testinal function, as heralded by the passage of flatus, was not a
requirement for discharge, the effect of return of gastrointestinal
function on LoS was not examined. However, Hendry and col-
leagues16 undertook a randomized controlled trial in which they
examined the effects of laxatives, preoperative carbohydrate
loading and postoperative oral nutritional supplements on the
return of gastrointestinal function following open hepatic resec-
tion. They found that those in the laxative group passed bowel
motions sooner at a median of 4 days versus 5 days in patients
who did not receive laxatives. However, despite this earlier return
of gastrointestinal function, Hendry et al. did not show a reduc-
tion in the duration of hospitalization.16 A further consideration
refers to the role of perioperative i.v. fluids in the return of gut
function. Although no studies of this factor in patients undergo-
ing liver resection were identified, data from studies of bowel
surgery indicate that liberal fluid prescription results in delayed
return of gut function because it promotes gut oedema.17
Although the present study showed an apparent increase in LoS
with higher volumes of i.v. fluids infused, this disappeared when
those patients who developed complications were excluded.
However, because the present study did not collect data on the
passage of flatus or return of bowel function, whether there was an
effect on gut function remains unknown.
In conclusion, the introduction of an ERAS programme follow-
ing open hepatic resection has resulted in a reduction in hospital
LoS with no evidence of an increase in complications. Readmis-
sions increase as hospital LoS reduces. No single factor within the
ERAS package would appear to be an independent predictor of
LoS.
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